Main > ONCOLOGY (**) > Leukemia>Lymphoblastic>Acute>Ph-R/R > Treatment > USA. A. BiTE MAb for Injection

---

USA. A. BiTE MAb for Injection's subsections
(*) CA Approval Date: ?
(*) CN Approval Date: 2022. 05.04
(*) JP Approval Date: 2018. 09.25.
(*) USA OK Date: 2018. 03.29>
BITE: BIspecific CD19-directed CD3>
Company
Company Licensee CN
Generic Name: BlinatumoMAb
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 6
Patent>UpDate: 2022. 07.05
RTM
RTM Web-Site
UpDate: 2018. 03.29

USA. A. BiTE MAb for Injection's products
This section has no products